# EMRELIS

NDC: 0074-1044
Generic name: Telisotuzumab Vedotin
Labeler / Manufacturer: AbbVie Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Routes: INTRAVENOUS
Marketing started: 20250514

FDA application: BLA761384

## Active ingredients

- TELISOTUZUMAB VEDOTIN: 20 mg/mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0074-1044"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0074-1044
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bc04f980-3957-4e35-ab81-8ec2ffe87215